Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden

A better understanding of the underlying disease biology that leads to improvement in treatment outcomes is needed. Investigation of the genomic landscape of Hodgkin lymphoma has been difficult because of the low tumor content in these inflammatory cell‐ and stroma‐rich tissue samples. A comprehensive genomic profiling with targeted next‐generation sequencing panel was performed to test for genomic aberrations in archival tumor samples from patients with Hodgkin lymphoma to identify potentially actionable molecular targets.

[1]  Y. Natkunam,et al.  PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  F. Jardin,et al.  Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma , 2016, Haematologica.

[3]  C. Copie-Bergman,et al.  Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B‐cell lymphoma , 2016, American journal of hematology.

[4]  Alex M. Fichtenholtz,et al.  Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. , 2016, Blood.

[5]  Philip J. Stephens,et al.  Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. , 2016 .

[6]  O. Elemento,et al.  Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. , 2015, Blood.

[7]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[8]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[9]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[10]  F. Hosoda,et al.  Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma , 2012, BMC Cancer.

[11]  D. Linch,et al.  Hodgkin's lymphoma in adults , 2012, The Lancet.

[12]  D. Sullivan,et al.  Nuclear export of proteins and drug resistance in cancer. , 2012, Biochemical pharmacology.

[13]  Razelle Kurzrock,et al.  PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Eric S. Lander,et al.  Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.

[15]  P. Hamilton,et al.  PARP inhibition induces BAX/BAK‐independent synthetic lethality of BRCA1‐deficient non‐small cell lung cancer , 2011, The Journal of pathology.

[16]  Michael R. Green,et al.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. , 2010, Blood.

[17]  A. Mottok,et al.  Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. , 2009, Blood.

[18]  W. Klapper,et al.  TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma , 2009, The Journal of experimental medicine.

[19]  P. Borst,et al.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.

[20]  N. Schmitz,et al.  Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  W. Klapper,et al.  Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. , 2006, Cancer research.

[22]  T. Mattfeldt,et al.  Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation , 2006, Oncogene.

[23]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[24]  J. Biegel,et al.  TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Inoki,et al.  Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. , 2003, Genes & development.

[26]  A. van den Berg,et al.  TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein‐Barr virus , 2001, International journal of cancer.

[27]  V. Diehl,et al.  Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. , 2000, Blood.

[28]  R Fauchet,et al.  Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course , 1998, British journal of haematology.

[29]  H. Griesser,et al.  Single-cell analysis of Hodgkin and Reed-Sternberg cells: molecular heterogeneity of gene expression and p53 mutations , 1993 .

[30]  K. Patel,et al.  Mutation of p53 in primary biopsy material and cell lines from Hodgkin disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[32]  N. Dubrawsky.  Cancer statistics , 2022 .